<div id="readability-page-1"><p>Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,603 shares of the firm's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $2.15, for a total transaction of $12,046.45. Following the completion of the sale, the chief executive officer directly owned 269,087 shares in the company, valued at $578,537.05. This represents a 2.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link.</p><div><p><span></span><span>Get <strong>Editas Medicine</strong> alerts:</span></p></div><h2>Editas Medicine Stock Up 2.5%</h2><ul><li>2 gene-editing stocks reshaping hereditary disease treatments </li></ul><p>NASDAQ:EDIT traded up $0.06 during midday trading on Thursday, hitting $2.43. The company had a trading volume of 1,570,206 shares, compared to its average volume of 2,730,958. The stock's fifty day moving average price is $3.12 and its 200-day moving average price is $2.70. Editas Medicine, Inc. has a 52-week low of $0.91 and a 52-week high of $4.54. The company has a market capitalization of $237.22 million, a PE ratio of -1.02 and a beta of 2.44. </p><p>Editas Medicine (NASDAQ:EDIT - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.10. The firm had revenue of $7.54 million during the quarter, compared to analysts' expectations of $4.95 million. Editas Medicine had a negative return on equity of 277.29% and a negative net margin of 430.84%. As a group, research analysts forecast that  Editas Medicine, Inc. will post -2.71 earnings per share for the current year. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>Are Gene Therapy Stocks The Market's Next Big Winners?</li></ul><p>A number of brokerages have recently issued reports on EDIT. HC Wainwright  reaffirmed a &#34;buy&#34; rating and set a $5.00 price objective on shares of Editas Medicine in a research note on Friday, September 5th. Wells Fargo &amp; Company lifted their price objective on Editas Medicine from $3.00 to $4.00 and gave the company an &#34;equal weight&#34; rating in a research report on Wednesday, September 3rd. Chardan Capital upgraded shares of Editas Medicine from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, November 13th. Wall Street Zen upgraded Editas Medicine from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Friday, September 26th. Finally, Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Editas Medicine in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned  a Buy rating, five have given a Hold rating and two have assigned  a Sell rating to the company. According to MarketBeat, the company  has an average rating of &#34;Hold&#34; and an average target price of $4.29.</p><p><b>View Our Latest Stock Analysis on EDIT</b></p><h2>Institutional Trading of Editas Medicine</h2><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. bought a new stake in  Editas Medicine during the 3rd quarter worth approximately $57,000.  Jacobs Levy Equity Management Inc. grew its holdings in  Editas Medicine by 761.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 800,023 shares of the company's stock valued at $2,776,000 after buying an additional 707,181 shares in the last quarter.  CANADA LIFE ASSURANCE Co raised its stake in  Editas Medicine by 43.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 45,754 shares of the company's stock valued at $161,000 after purchasing an additional 13,816 shares in the last quarter.  XTX Topco Ltd raised its position in shares of  Editas Medicine by 95.7% during the 3rd quarter. XTX Topco Ltd now owns 260,113 shares of the company's stock valued at $903,000 after buying an additional 127,176 shares in the last quarter.  Finally, Public Employees Retirement System of Ohio bought a new stake in shares of  Editas Medicine in the 3rd quarter valued at approximately $262,000. Hedge funds and other institutional investors own  71.90% of the company's stock. </p><h2>About Editas Medicine</h2> (Get Free Report)<p>Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Editas Medicine</li><li>How is Compound Interest Calculated?</li><li>Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF</li><li>Using the MarketBeat Dividend Yield Calculator</li><li>Strong Quarter, Weak Reaction: Why GitLab Shares Dropped</li><li>Dividend Payout Ratio Calculator</li><li>3 Signs Tesla Is Starting December on the Front Foot</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RURJVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RURJVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Editas Medicine Right Now?</h2><p>Before you consider Editas Medicine, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Editas Medicine wasn't on the list.</p><p>While Editas Medicine currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

EDIT

<p>Editas Medicine CEO Gilmore Neil O'neill sold 5,603 shares for $12,046.45, reducing his stake by 2.04%. Post-sale, he owns 269,087 shares valued at $578,537.05. The transaction was disclosed in a SEC filing. Editas stock rose 2.5% to $2.43, with a market cap of $237.22 million. Analysts have mixed ratings, with an average target price of $4.29. Institutional investors hold 71.90% of shares.</p>

Editas Medicine (NASDAQ:EDIT) CEO Sells $12,046.45 in Stock